SS-31 Is a Novel Mitochondrial-Targeted Therapy That Crosses Blood-Brain Barrier
Mitochondria play a vital role in cellular metabolism. Because of their widespread effects on cellular functions, mitochondrial dysfunction is implicated in a wide range of diseases. As such, mitochondria, the tiny energy factories found in most cells, are prime targets for drug development. But developing mitochondria-targeted drugs has been a daunting task.
Dr. Felsen received her BA degree from Queens College and her PhD in Pharmacology from the Mt. Sinai School of Medicine. She was a post-doctoral fellow in the laboratory of Dr. Philip Needleman in the Dept. of Pharmacology at Washington University in St. Louis, studying renal prostaglandin synthesis in the obstructed kidney. Following completion of the fellowship, she was recruited by then chairman E. Darracott Vaughan, Jr. to join the faculty at Weill Cornell.